Rapt Therapeutics (RAPT) Stock Price, News & Analysis

Company Overview

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

Key Stats

• Today's Range: $11.22 to $11.53
• 50-Day Range: $7.33 to $13.94
• 52-Week Range: $5.67 to $26.56
• Volume: 17,819 shs
• Average Volume: 108,451 shs
• Market Capitalization: $188.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.57
• Consensus Rating: Moderate Buy

Rapt Therapeutics Stock Analysis - MarketRank™

Rapt Therapeutics scored higher than 87% of companies evaluated by MarketBeat, and ranked 143rd out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Rapt Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Rapt Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Rapt Therapeutics are expected to grow in the coming year, from ($2.14) to ($1.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rapt Therapeutics is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rapt Therapeutics is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rapt Therapeutics has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.04% of the float of Rapt Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Rapt Therapeutics has a short interest ratio ("days to cover") of 4.1.

Change versus previous month

Short interest in Rapt Therapeutics has recently decreased by 11.01%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rapt Therapeutics does not currently pay a dividend.

Dividend Growth

Rapt Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.09

Percentage of Shares Shorted

5.04% of the float of Rapt Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Rapt Therapeutics has a short interest ratio ("days to cover") of 4.1.

Change versus previous month

Short interest in Rapt Therapeutics has recently decreased by 11.01%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: 0.94

News Sentiment

Rapt Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.09 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Rapt Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for RAPT on MarketBeat in the last 30 days. This is a decrease of -92% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Rapt Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.36% of the stock of Rapt Therapeutics is held by insiders.

Percentage Held by Institutions

99.09% of the stock of Rapt Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RAPT Stock Analysis - Frequently Asked Questions

How have RAPT shares performed this year?

Rapt Therapeutics' stock was trading at $12.64 at the beginning of the year. Since then, RAPT stock has decreased by 10.0% and is now trading at $11.38.

How were Rapt Therapeutics' earnings last quarter?

Rapt Therapeutics (NASDAQ:RAPT) issued its quarterly earnings results on Thursday, August, 7th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.61) by $0.04.

When did Rapt Therapeutics' stock split?

Rapt Therapeutics shares reverse split on Tuesday, June 17th 2025.The 1-8 reverse split was announced on Friday, June 13th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 16th 2025. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

When did Rapt Therapeutics IPO?

Rapt Therapeutics (RAPT) raised $39 million in an IPO on Thursday, October 31st 2019. The company issued 3,000,000 shares at $12.00-$14.00 per share. BMO Capital Markets, Wells Fargo Securities and UBS Investment Bank acted as the underwriters for the IPO.

Who are Rapt Therapeutics' major shareholders?

Rapt Therapeutics' top institutional investors include Medicxi Ventures Management Jersey Ltd (16.89%), Orbimed Advisors LLC (9.93%), TCG Crossover Management LLC (9.89%) and Foresite Capital Management VI LLC (9.45%). Insiders that own company stock include Dirk G Brockstedt, William Ho and Wendye Robbins.
View institutional ownership trends.

How do I buy shares of Rapt Therapeutics?

Shares of RAPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Rapt Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rapt Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 8/31/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RAPT
• CIK: 1673772
• Web: www.rapt.com
• Phone: (650) 489-9000
• Fax: N/A
• Employees: 80
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Rapt Therapeutics: $21.57
• High Price Target: $38.00
• Low Price Target: $9.00
• Potential Upside/Downside: +89.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($14.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$129.87 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -67.92%
• Return on Assets: -59.59%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.25
• Quick Ratio: 13.25

Sales & Book Value

• Annual Sales: $1.53 million
• Price / Sales: 123.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.94 per share
• Price / Book: 1.14

Miscellaneous

• Outstanding Shares: 16,540,000
• Free Float: 16,148,000
• Market Cap: $188.23 million
• Optionable: Optionable
• Beta: 0.01